Kolon Life Science Inc Market Cap ($99.35 Million)
Market Cap & Net Worth: Kolon Life Science Inc (102940)
Kolon Life Science Inc market cap. Kolon Life Science Inc (KQ:102940) has a market capitalization of $99.35 Million (₩146.60 Billion) as of November 4, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #19044 globally and #918 in its home market, demonstrating a -0.39% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kolon Life Science Inc's stock price ₩12850.00 by its total outstanding shares 11408200 (11.41 Million). Also see Kolon Life Science Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Kolon Life Science Inc Market Cap History (2015–2026)
Kolon Life Science Inc market cap history from 2015 to 2026. Data shows change from $989.61 Million to $99.35 Million (-17.08% CAGR). Check Kolon Life Science Inc stock quote for real-time trading data and today's change.
Index Memberships
Kolon Life Science Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$211.91 Billion | 0.05% | #361 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$211.91 Billion | 0.05% | #361 of 1384 |
Weight: Kolon Life Science Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Kolon Life Science Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kolon Life Science Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Kolon Life Science Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
Kolon Life Science Inc's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $989.61 Million | $121.18 Billion | $800.14 Million | 0.01x | 1.24x |
| 2016 | $605.09 Million | $158.28 Billion | $12.67 Billion | 0.00x | 0.05x |
| 2017 | $815.64 Million | $118.10 Billion | -$1.40 Billion | 0.01x | N/A |
| 2018 | $575.97 Million | $132.68 Billion | -$50.69 Billion | 0.00x | N/A |
| 2019 | $139.55 Million | $148.54 Billion | -$92.32 Billion | 0.00x | N/A |
| 2020 | $224.59 Million | $129.41 Billion | -$43.20 Billion | 0.00x | N/A |
| 2021 | $334.37 Million | $165.49 Billion | -$1.37 Billion | 0.00x | N/A |
| 2022 | $211.83 Million | $161.58 Billion | $2.13 Billion | 0.00x | 0.10x |
| 2023 | $198.69 Million | $124.64 Billion | -$30.73 Billion | 0.00x | N/A |
| 2024 | $177.82 Million | $161.39 Billion | -$93.09 Billion | 0.00x | N/A |
Competitor Companies of 102940 by Market Capitalization
Companies near Kolon Life Science Inc in the global market cap rankings as of November 4, 2026. Also see Kolon Life Science Inc total assets for a full breakdown of the balance sheet.
Key companies related to Kolon Life Science Inc by market ranking:
- Sam Chun Dang Pharm. Co. Ltd (KQ:000250): Ranked #5084 globally with a market cap of $2.67 Billion USD ( ₩3.94 Trillion KRW).
- ST Pharm Co.Ltd (KQ:237690): Ranked #8953 globally with a market cap of $916.61 Million USD ( ₩1.35 Trillion KRW).
- NatureCell Co.Ltd (KQ:007390): Ranked #9611 globally with a market cap of $793.12 Million USD ( ₩1.17 Trillion KRW).
- Oscotec Inc (KQ:039200): Ranked #10419 globally with a market cap of $674.16 Million USD ( ₩994.80 Billion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #5084 | Sam Chun Dang Pharm. Co. Ltd | KQ:000250 | $2.67 Billion | ₩183900.00 |
| #8953 | ST Pharm Co.Ltd | KQ:237690 | $916.61 Million | ₩72500.00 |
| #9611 | NatureCell Co.Ltd | KQ:007390 | $793.12 Million | ₩22050.00 |
| #10419 | Oscotec Inc | KQ:039200 | $674.16 Million | ₩35400.00 |
Market Capitalization of Kolon Life Science Inc (2015–2026)
Market capitalization of Kolon Life Science Inc from 2015 to today. Between 2015 and today, Kolon Life Science Inc's market cap moved from $989.61 Million to $ 99.35 Million, with a yearly change of -17.08%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩99.35 Million | -75.15% |
| 2025 | ₩399.70 Million | +124.78% |
| 2024 | ₩177.82 Million | -10.51% |
| 2023 | ₩198.69 Million | -6.20% |
| 2022 | ₩211.83 Million | -36.65% |
| 2021 | ₩334.37 Million | +48.88% |
| 2020 | ₩224.59 Million | +60.94% |
| 2019 | ₩139.55 Million | -75.77% |
| 2018 | ₩575.97 Million | -29.38% |
| 2017 | ₩815.64 Million | +34.80% |
| 2016 | ₩605.09 Million | -38.86% |
| 2015 | ₩989.61 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Kolon Life Science Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $99.35 Million USD |
| MoneyControl | $99.35 Million USD |
| MarketWatch | $99.35 Million USD |
| marketcap.company | $99.35 Million USD |
| Reuters | $99.35 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kolon Life Science Inc
Kolon Life Science Inc. provides biopharmaceuticals, active pharmaceutical ingredients, pyrithione antimicrobials, and water solutions primarily in South Korea. Its biopharmaceutical product under development comprise KLS-1020, a cancer vaccine; KLS-3021, a oncolytic viral therapy; and KLS-2031 for treatment for neuropathic pain. The company also provides active pharmaceutical ingredients for ant… Read more